BCTX Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of 42.95%. BriaCell Therapeutics Corp.'s return on equity of -318.28% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 1575.98%. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 3.01%. Given that BriaCell Therapeutics Corp. has higher upside potential than Aurinia Pharmaceuticals, Inc., analysts believe BriaCell Therapeutics Corp. is more attractive than Aurinia Pharmaceuticals, Inc..

BriaCell Therapeutics Corp. has a beta of 1.385, which suggesting that the stock is 38.504% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

BriaCell Therapeutics Corp. quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. BriaCell Therapeutics Corp.'s net income of -$8.3M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while Aurinia Pharmaceuticals, Inc.'s PE ratio is 28.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus 8.59x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of --. BriaCell Therapeutics Corp.'s return on equity of -318.28% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 1575.98%. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.55 which suggests that it could grow by 449.6%. Given that BriaCell Therapeutics Corp. has higher upside potential than Oncolytics Biotech, Inc., analysts believe BriaCell Therapeutics Corp. is more attractive than Oncolytics Biotech, Inc..

BriaCell Therapeutics Corp. has a beta of 1.385, which suggesting that the stock is 38.504% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

BriaCell Therapeutics Corp. quarterly revenues are --, which are smaller than Oncolytics Biotech, Inc. quarterly revenues of --. BriaCell Therapeutics Corp.'s net income of -$8.3M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pharmagreen Biotech, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of --. BriaCell Therapeutics Corp.'s return on equity of -318.28% beat Pharmagreen Biotech, Inc.'s return on equity of --.

BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 1575.98%. On the other hand Pharmagreen Biotech, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BriaCell Therapeutics Corp. has higher upside potential than Pharmagreen Biotech, Inc., analysts believe BriaCell Therapeutics Corp. is more attractive than Pharmagreen Biotech, Inc..

BriaCell Therapeutics Corp. has a beta of 1.385, which suggesting that the stock is 38.504% more volatile than S&P 500. In comparison Pharmagreen Biotech, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.83%.

BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharmagreen Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. Pharmagreen Biotech, Inc. pays out -- of its earnings as a dividend.

BriaCell Therapeutics Corp. quarterly revenues are --, which are smaller than Pharmagreen Biotech, Inc. quarterly revenues of $300. BriaCell Therapeutics Corp.'s net income of -$8.3M is lower than Pharmagreen Biotech, Inc.'s net income of $45.6K. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while Pharmagreen Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus 889.89x for Pharmagreen Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of -163.68%. BriaCell Therapeutics Corp.'s return on equity of -318.28% beat Venus Concept, Inc.'s return on equity of -1236.95%.

BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 1575.98%. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 5972.92%. Given that Venus Concept, Inc. has higher upside potential than BriaCell Therapeutics Corp., analysts believe Venus Concept, Inc. is more attractive than BriaCell Therapeutics Corp..

BriaCell Therapeutics Corp. has a beta of 1.385, which suggesting that the stock is 38.504% more volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.111, suggesting its less volatile than the S&P 500 by 111.094%.

BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

BriaCell Therapeutics Corp. quarterly revenues are --, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. BriaCell Therapeutics Corp.'s net income of -$8.3M is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus 0.04x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.